Histopathology of drug-induced liver disease

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 237-289

  Kanel, Gary C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46349087847     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (90)

1. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32(Suppl.):77-88.
2. Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998; 27:119-30.
3. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118-27.
4. Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:759-86.
5. Hall P de la M. Histopathology of drug-induced liver disease. In: Farrell GC, ed. Drug-Induced Liver Diseases. Edinburgh: Churchill Livingston, 1994:115-51.
6. Black M. Drug-induced liver disease. Clin Liver Dis 1998; 2:457-647.
7. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-85.
8. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005; 39(Suppl. 2):S83-9.
9. Park K, Williams DP, Naisbitt DJ, et al. Investigation of toxic metabolites during drug development. Toxicol Appl Pharmacol 2005; 207(2 Suppl.): 425-34.
10. Novak D, Lewis JH. Drug-induced liver disease. Curr Opin Gastroenterol 2003; 19:203-15.
11. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61:135-43.
12. Lee WM, Schiodt FV. Drug-induced liver disease. In: Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C, Powell DW, eds. Textbook of Gastroenterology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2003:2352-65.
13. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65:166-76.
14. Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N, ed. Liver and Biliary Diseases. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996:103-20.
15. Benhamos JP. Drug-induced hepatitis: clinical aspects. In: Fillastre JP, ed. Hepatotoxicity of Drugs. Rouen: Universitéde Rouen, 1985:22-30.
16. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
17. Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med Toxicol 1987; 2:112-60.
18. Matzen P, Malchow-Moller A, Hilden J, et al. Computer icterus group: differential diagnosis of jaundice: a pocket diagnostic chart. Liver 1984; 4:360-71.
19. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993; 9:441-9.
20. Devictor D, Desplanques L, Debray D, et al. Emergency liver transplantation for fulminant liver failure in infants and children. Hepatology 1992; 16:1156-62.
21. Hoofnagle JH, Carithers RL, Jr., Shapiro C, et al. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240-52.
22. Lewis JH, Zimmerman HJ. Drug-induced liver disease. Med Clin North Am 1989; 73:775-92.
23. Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RB, Anthony P, Scheuer P, Burt AD, Portmann BC, eds. Pathology of the Liver. 3rd ed. Edinburgh: Churchill Livingston, 1994:563-633.
24. Zimmerman HJ. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. 8th ed. Philadelphia, PA: Lippincott-Raven, 1999:973-1064.
25. DeLeve LD, Kaplowitz N. Mechanism of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24:787-810.
26. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995; 23(Suppl. 1):16-24.
27. Park BK, Kitteringham NR, Maggs JL, et al. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005; 45:177-202.
28. Zimmerman HJ, Ishak KG. Hepatic injury due to drugs and toxins. In: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, eds. Pathology of the Liver. 4th ed. London:Churchill Livingstone, 2002:621-709.
29. Lazerow SK, Abdi MS, Lewis JH. Drug-induced liver disease 2004. Curr Opin Gastroenterol 2005; 21:283-92.
30. Neuberger J. Immune mechanisms in drug hepatotoxicity. Clin Liver Dis 1998; 2:471-82.
31. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33:1-5.
32. Ju C. Immunological mechanisms of drug-induced liver injury. Curr Opin Drug Discov Devel 2005; 8:38-43.
33. Ganey PE, Luyendyk JP, Maddox JF, et al. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004; 150:35-51.
34. Kanel GC. Histopathology of drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. New York, NY: Marcel Dekker Inc., 2003:243-86.
35. Kanel GC, Korula J. Atlas of Liver Pathology. 2nd ed. Philadelphia, PA: Elsevier, 2005:78-115.
36. Farrell GC. Drug-induced chronic active hepatitis. In: Farrell GC, ed. Drug-Induced Liver Disease. Edinburgh: Churchill Livingston, 1994:413-30.
37. Zimmerman HJ. Update of hepatotoxicity due to classes of drugs in common clinical use: nonsteroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic agents. Semin Liver Dis 1990; 10:322-38.
38. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002; 22:195-206.
39. Bromer MQ, Black M. Acetaminophen hepatotoxicity. Clin Liver Dis 2003; 7:351-67.
40. Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38:33-8.
41. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005; 41:237-46.
42. Schiodt FV, Lee WM. Fulminant liver disease. Clin Liver Dis 2003; 7:331-49.
43. Dianzani MU. Toxic liver injury by protein synthesis inhibitors. Prog Liver Dis 1976; 5:232-45.
44. Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15:367-73.
45. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003; 7:435-51.
46. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9:37-53.
47. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9:679-85.
48. Poucell S, Ireton J, Valencia-Mayoral P, et al. Amiodarone associated phospholipidosis and fibrosis of the liver: light, immunohistochemical and electron microscopic studies. Gastroenterology 1984; 86:926-36.
49. Lullman H, Lullman-Rauch R. Drug induced lysosomal storage disease of the liver. In: Fillastre W, ed. Hepatotoxicity of Drugs. Rouen: Université de Rouen, 1986:127-37.
50. Kanel GC, Reynolds TB. Hepatic granulomas. In: Kaplowitz N, ed. Liver and Biliary Diseases. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996:455-62.
51. Ishak KG, Zimmerman HJ. Drug-induced and toxic granulomatous hepatitis. Baillieres Clin Gastroenterol 1988; 2:463-80.
52. French SW. The Mallory body: structure, composition and pathogenesis. Hepatology 1981; 1:76-83.
53. Kanel GC. Hepatic lesions resembling alcoholic liver disease. In: Ferrell LD, ed. Diagnostic Problems in Liver Pathology. Philadelphia, PA: Hanley & Belfus Inc., 1994:77-104.
54. Zetterman RK. Nonalcoholic steatohepatitis. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver. 8th ed. Philadelphia, PA: Lippincott-Raven, 1999:1179-83.
55. Phillips MJ, Poucell S, Patterson J, Valencia P. The Liver: An Atlas and Text of Ultrastructural Pathology. New York, NY: Raven Press, 1987:393-446.
56. Simon FR. Drug-induced cholestasis: pathobiology and clinical features. Clin Liver Dis 1998; 2:483-99.
57. Levy C, Lindor KD. Drug-induced cholestasis. Clin Liver Dis 2003; 7:311-30.
58. Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis 2004; 8:95-132.
59. Ishak KG. The liver. In: Riddell RH, ed. Pathology of Drug-Induced and Toxic Diseases. New York, NY: Churchill Livingston, 1982:457-513.
60. Guebel AP, Sempoux C, Rahier J. Bile duct disorders. Clin Liver Dis 2003; 7:295-309.
61. Ludwig J, Kim CH, Wiesner GH, et al. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy. Hepatology 1989; 9:215-8.
62. Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202:176-81.
63. Aldrighetti L, Arru M, Ronzoni M, et al. Extrahepatic biliary stenosis after hepatic arterial infusion (HAI) of floxuridine (FudR) for liver metastases from colorectal cancer. Hepatogastroenterology 2001; 48:1302-7.
64. Gitlin N. Drug-induced hepatic vascular abnormalities. Clin Liver Dis 1998; 2:591-606.
65. Zafrani ES, Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983; 143:495-502.
66. Bagheri SA, Boyer JL. Peliosis hepatis associated with androgenic-anabolic steroid therapy: a severe form of hepatic injury. Ann Intern Med 1974; 81:610-8.
67. Yanoff M, Rawson AJ. Peliosis hepatis: an anatomic study with demonstration of two varieties. Arch Pathol 1964; 77:159-65.
68. Staub PG, Leibowitz CB. Peliosis hepatis associated with oral contraceptive use. Australas Radiol 1996; 40:172-4.
69. Altmann H-W. Drug-induced liver reactions: a morphological approach. Curr Top Pathol 1980; 69:69-142.
70. Winkler K, Poulsen H. Liver disease with periportal sinusoidal dilatation: a possible complication to contraceptive steroids. Scand J Gastroenterol 1975; 10:699-704.
71. DeLeve LD, McCuskey RS, Xiangdong W, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29:1779-91.
72. Shulman HM, Fisher LB, Schoch HG, et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19:1171-80.
73. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5:306-15.
74. Schiano TD. Liver injury from herbs and other botanicals. Clin Liver Dis 1998; 2:607-30.
75. Maddrey WC. Hepatic vein thrombosis (Budd-Chiari syndrome): possible association with the use of oral contraceptives. Semin Liver Dis 1987; 7:32-9.
76. French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. VA Cooperative Study Group 119. Semin Liver Dis 1993; 13:154-69.
77. Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructural and histologic progression. Gastroenterology 1982; 83:777-85.
78. Goodman ZD, Ishak KG. Occlusive venous lesions in alcoholic liver disease: a study of 200 cases. Gastroenterology 1982; 83:786-96.
79. Patel T. Apoptosis in hepatic pathophysiology. Clin Liver Dis 2000; 4:295-317.
80. Rockey DC. The cell and molecular biology of hepatic fibrogenesis: clinical and therapeutic implications. Clin Liver Dis 2000; 4:319-55.
81. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999; 14:618-33.
82. Popper H, Thomas LB, Telles NC, et al. Development of hepatic angiosarcoma in man induced by vinyl chloride, thorotrast, and arsenic: comparison with cases of unknown etiology. Am J Pathol 1978; 92:349-76.
83. Almoudarres M, Vega KJ, Trotman BW. Noncirrhotic portal hypertension in the adult: case report and review of the literature. J Assoc Acad Minor Phys 1998; 9:53-5.
84. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211.
85. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294:470-2.
86. Tajada M, Nerin J, Ruiz MM, et al. Liver adenoma and focal nodular hyperplasia associated with oral contraceptives. Eur J Contracept Reprod Health Care 2001; 6:227-30.
87. Korula J, Yellin A, Kanel G, et al. Hepatocellular carcinoma coexisting with hepatic adenoma:incidental discovery after long-term oral contraceptive use. West J Med 1991; 155:416-8.
88. Falk H. Vinyl chloride-induced hepatic angiosarcoma. Princess Takamatsu Symp 1987; 18:39-46.
89. Centeno JA, Mullick FG, Martinez L, et al. Pathology related to chronic arsenic exposure. Environ Health Perspect 2002; 110(Suppl. 5):883-6.
90. Pamperl H, Gradner W, Frittlich H, et al. Influence of long-term anti-convulsant treatment on liver ultrastructure in man. Liver 1984; 4:294-300.